These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 34707573)

  • 21. Pathogenesis of and major animal models used for nonalcoholic fatty liver disease.
    Jiang M; Wu N; Chen X; Wang W; Chu Y; Liu H; Li W; Chen D; Li X; Xu B
    J Int Med Res; 2019 Apr; 47(4):1453-1466. PubMed ID: 30871397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis.
    Chung KW; Cho YE; Kim SJ; Hwang S
    Arch Pharm Res; 2022 Apr; 45(4):229-244. PubMed ID: 35391713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Options and Future Directions for NAFLD and NASH Treatment.
    Zhang C; Yang M
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2.
    Ye D; Yang K; Zang S; Lin Z; Chau HT; Wang Y; Zhang J; Shi J; Xu A; Lin S; Wang Y
    J Hepatol; 2016 Nov; 65(5):988-997. PubMed ID: 27266617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of vitamin E in nonalcoholic fatty liver disease.
    Nagashimada M; Ota T
    IUBMB Life; 2019 Apr; 71(4):516-522. PubMed ID: 30592129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. E-Selectin-Dependent Inflammation and Lipolysis in Adipose Tissue Exacerbate Steatosis-to-NASH Progression via S100A8/9.
    Rodrigues RM; He Y; Hwang S; Bertola A; Mackowiak B; Ahmed YA; Seo W; Ma J; Wang X; Park SH; Guan Y; Fu Y; Vanhaecke T; Feng D; Gao B
    Cell Mol Gastroenterol Hepatol; 2022; 13(1):151-171. PubMed ID: 34390865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies.
    Sunny NE; Bril F; Cusi K
    Trends Endocrinol Metab; 2017 Apr; 28(4):250-260. PubMed ID: 27986466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging Therapies and Therapeutic Targets for Composite Liver Disease: NASH.
    Sobhia ME; Kumari S; Kumar H; Gandhe A; Kaushik D; Kumar H; Jain J; Ankita ; Mallick M; Pavani B; Moudgil M; Patel D
    Curr Top Med Chem; 2023; 23(21):2027-2047. PubMed ID: 37455455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological inhibition of CFTR attenuates nonalcoholic steatohepatitis (NASH) progression in mice.
    Rajak S; Tewari A; Raza S; Gupta P; Chakravarti B; Anjum B; Tripathi M; Singh BK; Yen PM; Goel A; Ghosh S; Sinha RA
    Biochim Biophys Acta Mol Basis Dis; 2023 Apr; 1869(4):166662. PubMed ID: 36754244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets.
    Yang L; Hao Y; Boeckmans J; Rodrigues RM; He Y
    Pharmacol Ther; 2023 Mar; 243():108353. PubMed ID: 36738973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
    Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
    Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
    J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased ratio of neutrophil elastase to α1-antitrypsin is closely associated with liver inflammation in patients with nonalcoholic steatohepatitis.
    Zang S; Ma X; Zhuang Z; Liu J; Bian D; Xun Y; Zhang Q; Zhao F; Yang W; Liu J; Luo Y; Liu Y; Ye B; Ye D; Shi J
    Clin Exp Pharmacol Physiol; 2016 Jan; 43(1):13-21. PubMed ID: 26444279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.
    Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M
    Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.